Home
Kimberley Joanne Hatfield's picture

Kimberley Joanne Hatfield

Researcher , Researcher
  • E-mailKimberley.Hatfield@uib.no
  • Phone+47 55 97 30 37
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen

The main research aim is to characterize metabolic phenotypes of human leukemia cells, and investigate how metabolic pathways may be implicated in the development of cancer cells`drug resistance.
Additional research interests include the contribution of the microenvironment in acute myeloid leukemia (AML); in particular how leukemia cells are influenced by stromal cells and chemokines, and how leukemia cells adapt to changes in oxygen levels and nutrient availability.

  • 2020. The PI3K-AKT-MTOR signaling pathway in human acute myeloid leukemia (AML) cells. 1-22.
  • 2019. Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy. Cells.
  • 2019. Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. Signal Transduction and Targeted Therapy.
  • 2018. Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic and transcriptomic comparison. Expert opinion on therapeutic targets. 639-653.
  • 2018. The healthy donor profile of immunoregulatory soluble mediators is altered by stem cell mobilization and apheresis. Cytotherapy. 740-754.
  • 2018. Resistance to the antiproliferative in vitro effect of PI3K-Akt-mTOR inhibition in primary human acute myeloid leukemia cells is associated with altered cell metabolism. International Journal of Molecular Sciences. 1-18.
  • 2018. Patients with treatment-requiring chronic graft versus host disease after allogeneic stem cell transplantation have altered metabolic profiles due to the disease and immunosuppressive therapy: Potential implication for biomarkers. Frontiers in Immunology. 1-15.
  • 2018. Clonal heterogeneity reflected by pi3k-akt-mtor signaling in human acute myeloid leukemia cells and its association with adverse prognosis. Cancers. 1-15.
  • 2017. Granulocyte colony-stimulating factor alters the systemic metabolomic profile in healthy donors. Metabolomics. 1-10.
  • 2016. Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis. 172-185.

More information in national current research information system (CRIStin)

Bergen Research Foundation funded project: Characterization of metabolic phenotypes and signaling pathways in acute myeloid leukemia and their role in anti-leukemia treatment.